CLAIMS

1. An aqueous cagrilintide formulation comprising:
   - cagrilintide;
   - a buffer which is: glutamic acid/glutamate, in a concentration of about 2-10 mM; or lactic acid/lactate, in a concentration of about 2-35 mM; or acetic acid/acetate, in a concentration of about 2-10 mM;
   - 90-99% w/w water; and
   - a pH of 3.5-4.5, such as about pH 4.0.

2. An aqueous cagrilintide formulation comprising:
   - cagrilintide in a concentration of 0.1-20 mg/ml;
   - a buffer which is: glutamic acid/glutamate, in a concentration of about 2-10 mM; or lactic acid/lactate, in a concentration of about 2-35 mM; or acetic acid/acetate, in a concentration of about 2-10 mM; and
   - a pH of 3.5-4.5, such as about pH 4.0.

3. The cagrilintide formulation according to any one of claims 1-2, wherein the buffer is glutamic acid/glutamate in a concentration of 2-10 mM, such as 2.5-10 mM, such as 2.5-5 mM, such as 5-10 mM, such as 2-9 mM, such as 2-8 mM, such as 2.5-7.5 mM, such as 2-7 mM, such as 2-6 mM, such as 4-6 mM, such as about 5 mM.

4. The cagrilintide formulation according to any one of claims 1-3, further comprising a tonicity agent, such as glycerol, mannitol, propylene glycol, sorbitol, sucrose or trehalose.

5. An aqueous cagrilintide formulation comprising:
   - cagrilintide in a concentration of 0.1-20 mg/ml, such as about 1.0 mg/ml, such as about 2.0 mg/ml, such as at least 2 mg/ml, such as about 4.0 mg/ml, such as about 4.8 mg/ml, such as about 6.8 mg/ml, such as about 9.6 mg/ml, such as about 18 mg/ml;
   - glutamic acid/glutamate in a concentration of 2-10 mM, such as 2.5-10 mM, such as 2.5-5 mM, such as 5-10 mM, such as 2-9 mM, such as 2-8 mM, such as 2.5-7.5 mM, such as 2-7 mM, such as 2-6 mM, such as 4-6 mM, such as about 2.5-5.0 mM, such as about 5 mM;
   - glycerol in a concentration of 20-31 mg/ml, such as about 24 mg/ml;
   - a pH of 3.5-4.5, such as pH 4.0.

6. The cagrilintide formulation according to any one of claims 1-5 for use in an injection device.

7. The cagrilintide formulation according to any one of claims 1-6 for use in medicine.

8. An aqueous semaglutide formulation comprising:
   - semaglutide;
   - phosphate, in a concentration of more than 15 mM and less than or equal to 45 mM, such as 16-45 mM, such as 20-45 mM, such as 20-40 mM, such as 25-45 mM, such as 25-40 mM, such as 20-35 mM, such as 20-30 mM, such as 25-35 mM, such as about 30 mM;
   - 90-99% w/w water; and
   - a pH of 7.0-8.0, such as about 7.4.

9. An aqueous semaglutide formulation comprising:
   - semaglutide, in a concentration of 0.1-10 mg/ml;
   - phosphate, in a concentration of more than 15 mM and less than or equal to 45 mM, such as 16-45 mM, such as 20-45 mM, such as 20-40 mM, such as 25-45 mM, such as 25-40 mM, such as 20-35 mM, such as 20-30 mM, such as 25-35 mM, such as about 30 mM; and
   - a pH of 7-8, such as about 7.4.

10. The semaglutide formulation according to any one of claims 8-9, further comprising histidine.

11. The semaglutide formulation according to any one of claims 8-10, further comprising a tonicity agent, such as propylene glycol, potassium chloride and/or sodium chloride.

12. An aqueous semaglutide formulation comprising:
   - semaglutide in a concentration of 0.1-10 mg/ml, such as 0.5-10 mg/ml, such as 0.5-5.0 mg/ml, such as 0.5-4.8 mg/ml, such as about 0.5 mg/ml, such as about 1 mg/ml, such as about 2 mg/ml, such as about 3.4 mg/ml, such as about 4.8 mg/ml;
   - a phosphate buffer, such as disodium hydrogen phosphate, dihydrate, in a concentration of more than 15 mM and less than or equal to 45 mM, such as 16-45

mM, such as 20-45 mM, such as 20-40 mM, such as 25-45 mM, such as 25-40 mM, such as 20-35 mM, such as 20-30 mM, such as 25-35 mM, such as about 30 mM;
- sodium chloride in a concentration of 4.5-8.5 mg/ml, such as 5.0-8.5 mg/ml, such as 5.5-8.5 mg/ml, such as 6.0-8.5 mg/ml, such as 7.0-8.25 mg/ml, such as 4.5-7.0, such as 5.0-7.5 mg/ml, such as 5.0-7.0 mg/ml, such as 5.5-7 mg/ml, such as 6.4-7.9 mg/ml, such as 6.4-7.5 mg/ml, such as 6-7 mg/ml, such as above 6.4 mg/ml, such as about 5.4 mg/ml, such as about 6.4 mg/ml, such as about 6.7 mg/ml
- histidine in a concentration of less than about 20 mM, such as 1-20 mM, such as 5-15 mM, such as 8-12 mM, such as about 10 mM;
- a pH of 7.0-8.0, such as about 7.4.

13. The semaglutide formulation according to any one of claims 8-12 for use in an injection device.

14. The semaglutide formulation according to any one of claims 8-12, optionally in combination with the cagrilintide formulation according to any one of claims 1- 5, for use in medicine.

15. A medical device comprising semaglutide in a first chamber and cagrilintide in a second chamber.

16. A medical device comprising a first chamber and a second chamber, wherein the first chamber comprises the semaglutide formulation according to any one of claims 8-12 and the second chamber comprises the cagrilintide formulation according to any one of claims 1-5.

17. A medical device comprising a first chamber and a second chamber, wherein the first chamber comprises an aqueous semaglutide formulation comprising:
- semaglutide in a concentration of 0.1-10 mg/ml, such as 0.5-10 mg/ml, such as 0.5-5.0 mg/ml, such as 0.5-4.8 mg/ml, such as about 0.5 mg/ml, such as about 1 mg/ml, such as about 2 mg/ml, such as about 3.4 mg/ml, such as about 4.8 mg/ml;
- a phosphate buffer, such as disodium hydrogen phosphate, dihydrate, in a concentration of more than 15 mM and less than or equal to 45 mM, such as 16-45 mM, such as 20-45 mM, such as 20-40 mM, such as 25-45 mM, such as 25-40 mM, such as 20-35 mM, such as 20-30 mM, such as 25-35 mM, such as about 30 mM;

- sodium chloride in a concentration of 4.5-8.5 mg/ml, such as 5.0-8.5 mg/ml, such as 5.5-8.5 mg/ml, such as 6.0-8.5 mg/ml, such as 7.0-8.25 mg/ml, such as 4.5-7.0, such as 5.0-7.5 mg/ml, such as 5.0-7.0 mg/ml, such as 5.5-7 mg/ml, such as 6.4-7.9 mg/ml, such as 6.4-7.5 mg/ml, such as 6-7 mg/ml, such as above 6.4 mg/ml, such as about 5.4 mg/ml, such as about 6.4 mg/ml, such as about 6.7 mg/ml;
- histidine in a concentration of less than about 20 mM, such as 1-20 mM, such as 5-15 mM, such as 8-12 mM, such as about 10 mM.
- a pH of 7.0-8.0, such as about 7.4; and wherein

the second chamber comprises an aqueous cagrilintide formulation comprising:

- cagrilintide in a concentration of 0.1-20 mg/ml, such as about 1.0 mg/ml, such as about 2.0 mg/ml, such as at least 2 mg/ml, such as about 4.0 mg/ml, such as about 4.8 mg/ml, such as about 6.8 mg/ml, such as about 9.6 mg/ml, such as about 18 mg/ml;
- glutamic acid/glutamate, in a concentration of 2-10 mM, such as 2.5-10 mM, such as 2.5-5 mM, such as 5-10 mM, such as 2-9 mM, such as 2-8 mM, such as 2.5-7.5 mM, such as 2-7 mM, such as 2-6 mM, such as 4-6 mM, such as about 2.5-5.0 mM, such as about 5 mM;
- a tonicity agent which is glycerol, in a concentration of 20-31 mg/ml, such as about 24 mg/ml;
- a pH of 3.5-4.5, such as pH 4.0.

18. The medical device according to claim 15-17, wherein the first chamber is a distal chamber and the second chamber is a proximal chamber.

19. A fixed-dose combination of 0.025-5.0 mg cagrilintide and 0.05-5.0 mg semaglutide for use in medicine, wherein the cagrilintide and semaglutide are administered parenterally, such as subcutaneously, in a single injection.